Minim Makes Direct E-Commerce Play with the Launch of a New Site and Promotions for Consumers and ISPs

Company unveils MotorolaNetwork.com with deal alerts, online support channels, and new products; releases Motorola AC2200 Smart Router at highly competitive price

MANCHESTER, NH, Nov. 23, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Minim, Inc. (NASDAQ: MINM), the creator of intelligent networking products under the globally recognized Motorola brand, today unveils MotorolaNetwork.com, an e-commerce site with deals for consumers and broadband service providers. With this launch, the company is also releasing the value-packed Motorola AC2200 Smart Router at just $99.99, bringing high-performance WiFi and the motosync app to apartments and small homes. 

Motorola has been synonymous with high-speed cable modems for more than 20 years, and the networking lineup has recently expanded to include high-performance mesh system and router products. Starting today on MotorolaNetwork.com, the Motorola AC2200 Smart Router (MH7021-10S) makes its debut, offering: 

●      Robust WiFi coverage up to 2,000 square feet

●      Connection management of up to 100 devices

●      Attractive design, ready for any shelf

●      motosync mobile app with advanced security, parental controls, data tracking, and more 

●      2-year warranty 

The Motorola AC2200 Smart Router is price competitive in the smart router category, wherein security and parental controls typically come at an additional fee.

“Our priority is to make it easy for customers to secure and personalize home networks with motosync, powered by Minim,” said Nicole Zheng, President and CMO at Minim. “While we are focused on continued sales growth in leading retailers and online marketplaces, we wanted to offer a single destination for making a strong connection with Motorola networking solutions. Now, both consumers and ISP partners can find the latest products and software features on MotorolaNetwork.com and sign up for promotions. We’re just getting started.”  

MotorolaNetwork.com visitors will find information about the latest features in the motosync mobile app. The new e-commerce destination also enables broadband service providers to purchase hardware/software bundled products in bulk at volume discount pricing offered by Minim. To learn more, visit MotorolaNetwork.com.

About Minim

Minim
, Inc. (NASDAQ: MINM) is the creator of intelligent networking products that dependably connect people to the information they need and the people they love. Headquartered in Manchester, NH, the company delivers smart software-driven communications products under the globally recognized Motorola brand and Minim® trademark. Minim end users benefit from a personalized and secure WiFi experience, leading to happy and safe homes where things just work. To learn more, visit https://www.minim.com.

MOTOROLA and the Stylized M Logo are trademarks or registered trademarks of Motorola Trademark Holdings, LLC and are used under license.

Media Contact:  

Nicole Zheng at (908) 337-2481 or [email protected]

Investor Relations Contact:

James Carbonara, Hayden IR at (646) 755-7412 or [email protected]


About Motorola Strategic Brand Partnerships

For over 90 years the Motorola brand has been known around the world for high quality, innovative and trusted products. Motorola’s Strategic Brand Partnership program seeks to leverage the power of this iconic brand by teaming with dynamic companies who offer unique, high quality products that enrich consumers’ lives. Strategic brand partners work closely with Motorola engineers while developing and manufacturing their products, ensuring that their products meet the exacting safety, quality, and reliability standards that consumers have come to expect from Motorola. To learn more about Motorola strategic brand partnerships, follow us @ShopMotorola.


Forward-Looking Statements

This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.  Such forward-looking statements relate to Minim’s plans, expectations, and intentions. Actual results may be materially different from expectations as a result of known and unknown risks, including: risks associated with Minim’s potential inability to realize intended benefits of the acquisition by merger of Zoom Connectivity, Inc.; the potential increase in tariffs on the company’s imports; the potential supply interruptions from manufacturing the company’s products in Vietnam; risks relating to global semiconductor shortages; potential changes in NAFTA; the potential need for additional funding which Minim may be unable to obtain; declining demand for certain of Minim’s products; delays, unanticipated costs, interruptions or other uncertainties associated with Minim’s production and shipping; Minim’s reliance on several key outsourcing partners; uncertainty of key customers’ plans and orders; risks relating to product certifications; Minim’s dependence on key employees; uncertainty of new product development, including certification and overall project delays, budget overruns; the risk that newly introduced products may contain undetected errors or defects or otherwise not perform as anticipated; costs and senior management distractions due to patent related matters; risks from a material weakness in our internal control over financial reporting; the impact of the COVID-19 pandemic; and other risks set forth in Minim’s filings with the Securities and Exchange Commission. Minim cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Minim expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in Minim’s expectations or any change in events, conditions or circumstance on which any such statement is based.

Attachment



InMed Pharmaceuticals to Participate in Cowen’s 4th Annual Cannabis Conference

VANCOUVER, British Columbia, Nov. 23, 2021 (GLOBE NEWSWIRE) — InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the development, manufacturing and commercialization of rare cannabinoids, today announced that InMed’s management team is scheduled to participate in Cowen’s 4th Annual Cannabis Conference to be held virtually on November 29 – December 1, 2021.

Cowen’s 4th Annual Cannabis Conference

Date: November 29 – December 1, 2021

Management will be available for virtual one-on-one meetings with institutional and corporate clients of the firm. To request 1-on-1 meetings with the Company, please contact your Cowen institutional representative or visit the conference website at https://www.cowen.com/conferences-and-events/4th-annual-cannabis-conference/

Cowen’s 4th Annual Cannabis Conference is a three-day conference comprising of topical panel discussions with C-Suite presenters, hosted by Cowen Research and Washington Research Group analysts, and virtual one-on-one meetings.

About InMed: InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the Company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

Investor Contact:

Colin Clancy
Senior Director, Investor Relations
T: +1 604 416 0999
E: cclancy@inmedpharma.com

Edison Group
:

Joe Green/Laine Yonker
T: +1.646.653.7030/+1.646.653.7035
E: [email protected] / [email protected]

Cautionary Note Regarding Forward-Looking Information:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: participating in Cowen’s 4th Annual Cannabis Conference; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.



Zai Lab Announces Upcoming Presentations at December Investor Conferences

SHANGHAI, SAN FRANCISCO and CAMBRIDGE, Mass., Nov. 23, 2021 (GLOBE NEWSWIRE) — Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688), a patient-focused, innovative, commercial-stage, global biopharmaceutical company, today announced that management from Zai Lab will be presenting at the following virtual investor conferences in December:

The 4th Annual Evercore ISI HealthCONx Conference

Fireside Chat: Wednesday, December 1, 2021, 8:25 a.m. ET

SVB Leerink CybeRx Series: Global Biopharma Spotlight

Fireside Chat: Wednesday, December 8, 2021, 9:00 a.m. ET

Webcast link of the 4th Evercore ISI HealthCONx Conference will be available under “Events & Presentations” in the “Investor Relations” section of Zai Lab’s website. An archived replay will be available for 90 days following the event.

About Zai Lab

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is a patient-focused, innovative, commercial-stage, global biopharmaceutical company focused on developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. To that end, our experienced team has secured partnerships with leading global biopharmaceutical companies in order to generate a broad pipeline of innovative marketed products and product candidates. We have also built an in-house team with strong product discovery and translational research capabilities and are establishing a pipeline of proprietary product candidates with global rights. Our vision is to become a leading global biopharmaceutical company, discovering, developing, manufacturing and commercializing our portfolio in order to impact human health worldwide.

For additional information about the company, please visit www.zailaboratory.com or follow us at www.twitter.com/ZaiLab_Global.

For more information, please contact:

ZAI LAB CONTACTS:

Investor Relations: Ron Aldridge / Lina Zhang
+1 (781) 434-8465 / +86 136 8257 6943
[email protected] / [email protected]

Media: Danielle Halstrom / Xiaoyu Chen
+1 (215) 280-3898 / +86 185 0015 5011
[email protected] / [email protected] 

Zai Lab Limited

Source: Zai Lab Limited



Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics™”, today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York. The program aims to become one of the first hospital-based clinical sites to offer psychedelic medicine in the United States.

Lenox Hill Hospital is a 450-bed, acute care facility on Manhattan’s Upper East Side and the flagship Manhattan hospital of Northwell Health – the largest healthcare system in New York State. Highlights of the program include:

  • Founded by Kimia Pourrezaei, DO, and Gregory Mendoza, LCSW-R, of the Lenox Hill Hospital Outpatient Center for Mental Health, the clinical program is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations;
  • The program will increase accessibility by offering treatment with no out of pocket cost for individuals who would otherwise be unable to afford this service;
  • The clinic plans to also provide psychedelic treatments to frontline healthcare workers affected by COVID-19;
  • Clinicians will receive training in MDMA-, ketamine-, and tryptamine-assisted psychotherapy.

Clinicians will also receive training in EMBARK, a transdiagnostic psychedelic psychotherapy model that can be adapted to address a range of clinical indications and populations. EMBARK is Cybin’s psychotherapy model created by Dr. Alex Belser, Cybin’s Chief Clinical Officer and Bill Brennan, Ph.D. (cand.).

“Lenox Hill Hospital is excited by the potential of these modalities for the treatment of previously intractable conditions such as severe depression, chronic PTSD, and OCD,” said David Roane, MD, Chairman of Psychiatry at Lenox Hill Hospital. “With this grant from Cybin, Lenox Hill Hospital aims to become one of the first hospital-based clinical sites offering psychedelic medicine in the country and is dedicated to addressing health inequities by prioritizing care for marginalized and underserved populations. In particular, people of color are greatly underrepresented in psychedelic research studies and our team is committed to inclusive recruitment of patients.”

“It’s time for psychedelic medicine to climb down from the ivory tower and into the community. We are honored to support this program at Lenox Hill Hospital to start a low-cost/no-cost psychedelic-clinic for marginalized and underserved communities in New York,” said Dr. Alex Belser, Chief Clinical Officer of Cybin.

About Cybin

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in the USA, UK and Ireland. The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

About Lenox Hill Hospital

Lenox Hill Hospital, a member of Northwell Health, is a 450-bed, fully accredited, acute care hospital located on Manhattan’s Upper East Side with a national reputation for outstanding patient care and innovative medical and surgical treatments. U.S. News & World Report has ranked Lenox Hill among the nation’s best for cardiology and heart surgery; diabetes and endocrinology; ear, nose and throat; geriatrics; gynecology; neurology and neurosurgery; and orthopedics. In addition, the hospital received “high performing” designations from U.S. News for its performance in cancer, gastroenterology and GI surgery, pulmonology and lung surgery, and urology. For more information, go to www.lenoxhill.northwell.edu.

Cautionary Notes and Forward-Looking Statements

Certain statements in this press release constitute forward-looking information. All statements other than statements of historical fact contained in this press release, including, without limitation, statements regarding Cybin’s future, strategy, plans, objectives, goals and targets, and any statements preceded by, followed by or that include the words “believe”, “expect”, “aim”, “intend”, “plan”, “continue”, “will”, “may”, “would”, “anticipate”, “estimate”, “forecast”, “predict”, “project”, “seek”, “should” or similar expressions or the negative thereof, are forward-looking statements. Forward-looking statements in this news release include statements regarding the Company’s proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens to potentially treat psychiatric disorders.

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: implications of the COVID-19 pandemic on the Company’s operations; fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; and the risk factors set out in the Company’s management’s discussion and analysis for the period ended September 30, 2021 and the Company’s listing statement dated November 9, 2020, which are available under the Company’s profile on www.sedar.com and with the U.S. Securities and Exchange Commission on EDGAR at www.sec.gov. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cybin makes no medical, treatment or health benefit claims about Cybin’s proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocybin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Cybin has not conducted clinical trials for the use of its proposed products. Any references to quality, consistency, efficacy and safety of potential products do not imply that Cybin verified such in clinical trials or that Cybin will complete such trials. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin’s performance and operations.

Neither the Neo Exchange Inc. nor the NYSE American LLC stock exchange have approved or disapproved the contents of this news release and are not responsible for the adequacy and accuracy of the contents herein.

Investor & Media:

Leah Gibson

Vice President, Investor Relations

Cybin Inc.

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Mental Health Health Hospitals Other Health Pharmaceutical Biotechnology

MEDIA:

Logo
Logo

Kura Oncology to Participate in Two Upcoming Investor Conferences

SAN DIEGO, Nov. 23, 2021 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences:

  • A fireside chat at the Evercore ISI 4th Annual HealthCONx Conference at 11:20 a.m. ET / 8:20 a.m. PT on November 30, 2021; and
  • A fireside chat at the JMP Securities Hematology and Oncology Summit at 2:20 p.m. ET / 11:20 a.m. PT on December 7, 2021.

Audio webcasts of the Evercore and JMP events will be available in the Investors section of Kura’s website at www.kuraoncology.com, with archived replays available following both events.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1/2 clinical trial (KOMET-001) and targeting patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
[email protected]

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
[email protected]

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
[email protected]



American Eagle Outfitters Reports Record Third Quarter Results with Revenue Rising 24% and Operating Income More Than Doubling. This Reflects Strong Customer Demand and Excellent Execution on the “Real Power. Real Growth.” Value Creation Plan

American Eagle Outfitters Reports Record Third Quarter Results with Revenue Rising 24% and Operating Income More Than Doubling. This Reflects Strong Customer Demand and Excellent Execution on the “Real Power. Real Growth.” Value Creation Plan

Third Quarter 2021 Highlights Compared to Third Quarter 2020

  • Record revenue of $1.27 billion increased 24%
  • Operating income of $210 million more than doubled, reaching a new third quarter high
  • Strong demand, higher full-priced sales, reduced promotions and controlled costs fueled gross margin expansion to 44.3% and operating margin to 16.5%
  • American Eagle net revenue rose 21% and operating income was up 68%
  • Aerie net revenue increased 28% and operating income rose 46%

PITTSBURGH–(BUSINESS WIRE)–
American Eagle Outfitters, Inc. (NYSE: AEO) today announced financial results for the third quarter ended October 30, 2021.

“As strong demand for our merchandise and brands continues, I’m very pleased to report another quarter of record revenue and profit. The work on our Real Power. Real Growth. value creation plan is driving meaningful improvements to our profitability through real estate and inventory optimization; omni-channel and customer focus; and our supply chain initiatives. The power of our brands, operations and talent are clearly evident and we are intensely focused on ensuring these strengths continue to take AEO to new heights,” said Jay Schottenstein, AEO’s Executive Chairman of the Board and Chief Executive Officer.

“This quarter, we took an important next step in our supply chain transformation with the planned acquisition of Quiet Logistics to ensure ongoing efficiencies and procure a state-of-the-art logistics platform with meaningful growth potential. With our customer-first focus, the teams did a great job bringing in goods to meet strong demand this holiday season. I am extremely proud of the team’s ability to execute with precision at a time of volatility and am confident that we will exceed $600 million of operating income for the year, well above the $550 million 2023 target,” Jay continued.

Third Quarter 2021 Results

  • Total net revenue increased $242 million, or 24% to $1.27 billion, compared to $1.03 billion in the third quarter of 2020.
  • Aerie revenue of $315 million rose 28% from third quarter 2020 on top of 34% growth last year. American Eagle revenue of $941 million rose 21% versus third quarter 2020 following an 11% decline last year.
  • Consolidated store revenue increased 29%. Total digital revenue increased 10%. Compared to the pre-pandemic third quarter 2019 base, store revenue increased 9% and digital revenue increased 42%.
  • Gross profit of $565 million rose 36% from $415 million in the third quarter of 2020.
  • Gross margin of 44.3% expanded 410 basis points from 40.2% in the third quarter of 2020 and reflected the highest rate since 2007. The increase from 2020 largely reflected leverage on rent and delivery, as well as strong product demand, higher full-priced sales, lower promotions and inventory optimization initiatives, partially offset by higher freight costs.
  • Selling, general and administrative expense leveraged 190 basis points as a rate to sales versus third quarter 2020 due to strong revenue growth and lower incentive compensation.
  • Depreciation and amortization expense of $41 million compared to $39 million in the third quarter of 2020 and leveraged 60 basis points as a rate to sales due to strong revenue growth.
  • Operating income was $210 million. This compared to operating income of $96 million in third quarter 2020 or $103 million on an adjusted basis. Aerie’s operating income of $52 million increased 46% from $36 million in the third quarter of 2020 and American Eagle’s operating income of $261 million increased 68% from $155 million in the third quarter of 2020.
  • Operating margin of 16.5% reflected the highest rate since 2007. Aerie’s operating margin of 16.5% expanded 200 bps from 2020 and American Eagle’s operating margin of 27.8% expanded 780 bps from 2020.
  • Average diluted shares outstanding were 205 million compared to 184 million in the third quarter of 2020. The increase primarily reflected 34 million shares of unrealized dilution associated with the company’s convertible notes.
  • EPS of $0.74. Adjusted EPS of $0.76 this quarter excludes $0.02 of non-cash interest expense on the company’s convertible notes.

Inventory

Total consolidated ending inventory at cost increased 32% to $740 million compared to a 13% decline last year. The increase was partially driven by higher air freight due to global supply chain disruptions.

Capital Expenditures

In the third quarter of 2021, capital expenditures totaled $58 million, and year to date totaled $144 million. For fiscal 2021, the company now expects capital expenditures to be at the low end of our prior guidance range of $250 to $275 million.

Cash Flow and Balance Sheet

The company ended the period with total cash of $741 million. This compares to $692 million in third quarter 2020.

Shareholder Returns

The company’s third quarter cash dividend of $30 million was paid during the quarter.

Conference Call and Supplemental Financial Information

Today, management will host a conference call and real time webcast at 9:30 a.m. Eastern Time. To listen to the call, dial 1-877-407-0789 or internationally dial 1-201-689-8562 or go to www.aeo-inc.com to access the webcast and audio replay. Additionally, a financial results presentation is posted on the company’s website.

Non-GAAP Measures

This press release includes information on non-GAAP financial measures (“non-GAAP” or “adjusted”), including consolidated adjusted operating income and earnings per share, excluding non-GAAP items. These financial measures are not based on any standardized methodology prescribed by U.S. generally accepted accounting principles (“GAAP”) and are not necessarily comparable to similar measures presented by other companies. Non-GAAP information is provided as a supplement to, not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. Management believes that this non-GAAP information is useful for an alternate presentation of the company’s performance, when reviewed in conjunction with the company’s GAAP consolidated financial statements, as it helps identify underlying trends in our business that could otherwise be masked by the effect of the items that we exclude in such non-GAAP measures. Accordingly, we believe that adjusted operating income provides useful information to investors and others in understanding and evaluating our operating results, enhancing the overall understanding of our past performance and future prospects, and allowing for greater transparency with respect to the key financial metrics used by our management in our financial and operational decision-making.

These amounts are not determined in accordance with GAAP and therefore, should not be used exclusively in evaluating the company’s business and operations. We encourage investors and others to review our financial information in its entirety, not to rely on any single financial measure and to view these non-GAAP financial measures in conjunction with the related GAAP financial measures.

About American Eagle Outfitters, Inc.

American Eagle Outfitters, Inc. (NYSE: AEO) is a leading global specialty retailer offering high-quality, on-trend clothing, accessories and personal care products at affordable prices under its American Eagle® and Aerie® brands. Our purpose is to show the world that there’s REAL power in the optimism of youth. The company operates stores in the United States, Canada, Mexico, and Hong Kong, and ships to 81 countries worldwide through its websites. American Eagle and Aerie merchandise also is available at more than 200 international locations operated by licensees in 33 countries. For more information, please visit www.aeo-inc.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This release and related statements by management contain forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995), which represent our expectations or beliefs concerning future events, including fourth quarter and annual fiscal 2021 results. All forward-looking statements made by the company involve material risks and uncertainties and are subject to change based on many important factors, some of which may be beyond the company’s control. Words such as “estimate,” “project,” “plan,” “believe,” “expect,” “anticipate,” “intend,” “potential,” and similar expressions may identify forward-looking statements. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise and even if experience or future changes make it clear that any projected results expressed or implied therein will not be realized. The following factors, in addition to the risks disclosed in Item 1A., Risk Factors, of our Annual Report on Form 10-K for the fiscal year ended January 30, 2021 and in any other filings that we may make with the Securities and Exchange Commission in some cases have affected, and in the future could affect, the company’s financial performance and could cause actual results for fiscal 2021 and beyond to differ materially from those expressed or implied in any of the forward-looking statements included in this release or otherwise made by management: the negative impacts of the COVID-19 pandemic and related operational disruptions; the risk that the company’s operating, financial and capital plans may not be achieved; our inability to anticipate customer demand and changing fashion trends and to manage our inventory commensurately; seasonality of our business; our inability to achieve planned store financial performance; our inability to react to raw material cost, labor and energy cost increases; our inability to gain market share in the face of declining shopping center traffic; our inability to respond to changes in e-commerce and leverage omni-channel demands; our inability to expand internationally; difficulty with our international merchandise sourcing strategies; challenges with information technology systems, including safeguarding against security breaches; and global economic, public health, social, political and financial conditions, and the resulting impact on consumer confidence and consumer spending, as well as other changes in consumer discretionary spending habits, which could have a material adverse effect on our business, results of operations and liquidity.

 
 
 
 

AMERICAN EAGLE OUTFITTERS, INC.

CONSOLIDATED BALANCE SHEETS

(Dollars in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

October 30,

 

January 30,

 

October 31,

 

 

 

2021

 

2021

 

2020

ASSETS    
Cash and cash equivalents $ 740,668   $ 850,477   $ 692,356
Merchandise inventory 739,808   405,445   559,961
Accounts receivable, net 228,461   146,102   124,560
Prepaid expenses and other 66,593   120,619   130,909
Total current assets 1,775,530   1,522,643   1,507,786
Property and equipment, at cost, net of accumulated depreciation 665,408   623,808   650,397
Operating lease right-of-use assets 1,148,108   1,155,965   1,243,311
Intangible assets net, including goodwill 69,332   70,332   50,864
Non-current deferred income taxes 57,753   33,045   12,774
Other assets 33,884   29,013   33,083
Total Assets $ 3,750,015   $ 3,434,806   $ 3,498,215
   
LIABILITIES AND STOCKHOLDERS’ EQUITY    
Accounts payable $ 314,561   $ 255,912   $ 304,552
Current portion of operating lease liabilities 299,693   328,624   346,321
Accrued compensation and payroll taxes 123,588   142,272   117,736
Other current liabilities and accrued expenses 56,090   55,343   47,587
Unredeemed gift cards and gift certificates 42,070   62,181   39,794
Accrued income taxes and other 33,570   14,150   15,503
Dividends payable     22,843
Total current liabilities 869,572   858,482   894,336
Non-current operating lease liabilities 1,123,681   1,148,742   1,196,755
Long-term debt, net 336,249   325,290   321,081
Other non-current liabilities 23,816   15,627   17,846
Total non-current liabilities 1,483,746   1,489,659   1,535,682
Commitments and contingencies    
Preferred stock    
Common stock 2,496   2,496   2,496
Contributed capital 627,264   663,718   655,891
Accumulated other comprehensive loss (39,049 )   (40,748 )   (44,673 )
Retained earnings 2,185,393   1,868,613   1,865,370
Treasury stock (1,379,407 )   (1,407,414 )   (1,410,887 )
Total stockholders’ equity 1,396,697   1,086,665   1,068,197
Total Liabilities and Stockholders’ Equity $ 3,750,015   $ 3,434,806   $ 3,498,215
Current Ratio 2.04   1.77   1.69
 
 
 
 
 

AMERICAN EAGLE OUTFITTERS, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS

(Dollars and shares in thousands, except per share amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

GAAP Basis

 

 

13 Weeks Ended

 

 

October 30,

 

% of

 

 

October 31,

 

% of

 

 

2021

 

Revenue

 

 

2020

 

Revenue

Total net revenue $

1,274,078

 

100.0

%

  $

1,031,617

 

100.0

%

Cost of sales, including certain buying, occupancy and warehousing expenses

709,554

 

55.7

%

 

616,840

 

59.8

%

Gross profit

564,524

 

44.3

%

 

414,777

 

40.2

%

Selling, general and administrative expenses

313,890

 

24.6

%

 

273,297

 

26.5

%

Restructuring and COVID-19 related charges

 

0.0

%

 

6,955

 

0.6

%

Depreciation and amortization expense

40,947

 

3.2

%

 

38,974

 

3.8

%

Operating income (loss)

209,687

 

16.5

%

 

95,551

 

9.3

%

Interest expense, net

8,612

 

0.7

%

 

7,924

 

0.8

%

Other (income), net

(3,130

)

-0.2

%

 

(2,223

)

-0.2

%

Income (loss) before income taxes

204,205

 

16.0

%

 

89,850

 

8.7

%

Provision (benefit) from income taxes

51,981

 

4.1

%

 

31,742

 

3.1

%

Net income (loss) $

152,224

 

11.9

%

  $

58,108

 

5.6

%

   
Net income (loss) per basic share $

0.91

 

  $

0.35

 

Net income (loss) per diluted share $

0.74

 

  $

0.32

 

   
Weighted average common shares outstanding – basic

167,637

 

 

166,185

 

Weighted average common shares outstanding – diluted

205,013

 

 

184,397

 

   
 

GAAP Basis

39 Weeks Ended

October 30,

 

% of

 

 

October 31,

 

% of

2021

 

Revenue

 

 

2020

 

Revenue

Total net revenue $

3,502,848

 

100.0

%

  $

2,466,819

 

100.0

%

Cost of sales, including certain buying, occupancy and warehousing expenses

1,999,743

 

57.1

%

 

1,758,537

 

71.3

%

Gross profit

1,503,105

 

42.9

%

 

708,282

 

28.7

%

Selling, general and administrative expenses

872,320

 

24.9

%

 

685,206

 

27.8

%

Impairment, restructuring and COVID-19 related charges

 

0.0

%

 

177,186

 

7.1

%

Depreciation and amortization expense

119,674

 

3.4

%

 

120,818

 

4.9

%

Operating income (loss)

511,111

 

14.6

%

 

(274,928

)

-11.1

%

Interest expense, net

26,038

 

0.7

%

 

16,617

 

0.7

%

Other (income), net

(6,354

)

-0.2

%

 

(793

)

0.0

%

Income (loss) before income taxes

491,427

 

14.1

%

 

(290,752

)

-11.8

%

Provision (benefit) from income taxes

122,226

 

3.6

%

 

(77,943

)

-3.2

%

Net income (loss) $

369,201

 

10.5

%

  $

(212,809

)

-8.6

%

   
Net income (loss) per basic share $

2.20

 

  $

(1.28

)

Net income (loss) per diluted share $

1.78

 

  $

(1.28

)

   
Weighted average common shares outstanding – basic

168,062

 

 

166,385

 

Weighted average common shares outstanding – diluted

207,032

 

 

166,385

 

 
 
 
 
 

AMERICAN EAGLE OUTFITTERS, INC.

GAAP TO NON-GAAP RECONCILIATION

(Dollars in thousands, except per share amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

13 Weeks Ended

October 30, 2021

 

 

 

Interest Expense,

net

 

Net Income

 

Diluted Earnings

per Common Share

GAAP Basis

$

8,612

$

152,224

$

0.74

% of Revenue

 

0.7%

 

11.9%

 
Less: Convertible debt (1):

 

4,569

 

3,330

 

0.02

Non-GAAP Basis

$

4,043

$

155,554

$

0.76

% of Revenue

 

0.3%

 

12.2%

(1)

  Amortization of the non-cash discount on the Company’s convertible notes
 
 
 
 
 

AMERICAN EAGLE OUTFITTERS, INC.

GAAP TO NON-GAAP RECONCILIATION

(Dollars in thousands, except per share amounts)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

13 Weeks Ended

October 31, 2020

 

 

Operating Income

 

Interest

Expense, net

 

Net Income

 

Diluted Earnings

per Common Share

GAAP Basis

$

95,551

$

7,924

$

58,108

$

0.32

% of Revenue

 

9.3%

 

0.8%

 

5.6%

 
Add: Incremental COVID-19 related expenses and restructuring (1):

 

6,955

 

 

4,500

 

0.02

Less: Convertible debt (2):

 

 

4,113

 

2,657

 

0.01

Non-GAAP Basis

$

102,506

$

3,811

$

65,265

$

0.35

% of Revenue

 

9.9%

 

0.4%

 

6.2%

(1)

  $7.0 million incremental COVID-19 related expenses and restructuring charges:
        – $6.0 million of incremental COVID-19 related expenses consisting of personal
           protective equipment and supplies for our associates and customers
        – $1.0 million of corporate severance charges

(2)

  Amortization of the non-cash discount on the Company’s convertible notes
 
 
 
 
 

 AMERICAN EAGLE OUTFITTERS, INC.

RESULTS BY SEGMENT

(Dollars in thousands)

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

American Eagle

 

Aerie

 

Corporate(1)

 

Total(2)

13 weeks ended October 30, 2021                
Total net revenue  

 $

          940,992

 

 $

          315,049

 

 $

           18,037

 

 

 $

       1,274,078

 

Operating income (loss)  

 $

          261,225

 

 $

           52,021

 

 $

        (103,559

)

 

 $

          209,687

 

Capital Expenditures  

 $

           13,298

 

 $

           24,867

 

 $

           20,036

 

 

 $

           58,201

 

                 
13 weeks ended October 31, 2020                
Total net revenue  

 $

          775,961

 

 $

          246,748

 

 $

             8,908

 

 

 $

       1,031,617

 

Operating income (loss)  

 $

          155,259

 

 $

           35,738

 

 $

          (95,446

)

 

 $

           95,551

 

Restructuring and COVID-19 related charges  

 $

                  –  

 

 $

                  –  

 

 $

             6,955

 

 

 $

             6,955

 

Adjusted operating income (loss)  

 $

          155,259

 

 $

           35,738

 

 $

          (88,491

)

 

 $

          102,506

 

Capital Expenditures  

 $

           10,488

 

 $

             6,399

 

 $

           14,302

 

 

 $

           31,189

 

                 
   

American Eagle

 

Aerie

 

Corporate(1)

 

Total(2)

39 weeks ended October 30, 2021                
Total net revenue  

 $

       2,513,700

 

 $

          947,851

 

 $

           41,297

 

 

 $

       3,502,848

 

Operating income (loss)  

 $

          611,650

 

 $

          191,341

 

 $

        (291,880

)

 

 $

          511,111

 

Capital Expenditures  

 $

           36,093

 

 $

           48,164

 

 $

           60,148

 

 

 $

          144,405

 

                 
39 weeks ended October 31, 2020                
Total net revenue  

 $

       1,791,042

 

 $

          653,240

 

 $

           22,537

 

 

 $

       2,466,819

 

Operating income (loss)  

 $

             1,113

 

 $

           47,011

 

 $

        (323,052

)

 

 $

        (274,928

)

Impairment, restructuring, and COVID-19 related charges  

 $

           90,926

 

 $

           18,215

 

 $

           68,045

 

 

 $

          177,186

 

Adjusted operating income (loss)  

 $

           92,039

 

 $

           65,226

 

 $

        (255,007

)

 

 $

          (97,742

)

Capital Expenditures  

 $

           25,361

 

 $

           23,807

 

 $

           43,423

 

 

 $

           92,591

 

(1)

  Corporate includes revenue and operating results of the Todd Snyder and Unsubscribed brands, and AirTerra, which are not material to disclose as separate reportable segments. Corporate operating costs represents certain costs that are not directly attributable to another reportable segment.

(2)

  The difference between Total Operating Income (loss) and Income (loss) before Taxes includes the following items, which are not allocated to our reportable segments:
       –   For the 13 weeks ended October 30, 2021, interest expense, net or $8.6 million and other (income), net
           of ($3.1) million. For the 39 weeks ended October 30, 2021, interest expense, net of $26.0 million and other
           (income), net of ($6.4) million.
       –   For the 13 weeks  ended October 31, 2020, interest expense, net of $7.9 million and other (income), 
           net of ($2.2) million. For the 39 weeks ended October 31, 2020, interest expense, net of $16.6 million and other
           (income), net of ($0.8) million.
 
 
 
 
 

AMERICAN EAGLE OUTFITTERS, INC.

STORE INFORMATION

(unaudited)

 

 

 

 

 

 

 

Third Quarter

 

YTD Third Quarter

 

 

 

 

2021

 

2021

Consolidated stores at beginning of period

1,090

1,078

Consolidated stores opened during the period
AE Brand

3

14

Aerie stand-alone (incl. OFFLINE) (3)

25

43

Todd Snyder

0

1

Unsubscribed

2

3

AE77

1

1

Consolidated stores closed during the period
AE Brand

0

(18)

Aerie stand-alone (incl. OFFLINE)

0

(1)

Total consolidated stores at end of period

1,121

1,121

AE Brand

897

Aerie stand-alone (incl. OFFLINE) (3)

216

Aerie side-by-side (incl. OFFLINE) (2)(4)

187

Todd Snyder

3

Unsubscribed

4

AE77

1

 
Stores remodeled and refurbished during the period

2

13

Total gross square footage at end of period (in ‘000)

6,924

6,924

 
International license locations at end of period (1)

256

256

Aerie Openings
Aerie stand-alone (incl. OFFLINE) (3)

25

43

Aerie side-by-side (incl. OFFLINE) (2)(4)

4

9

Total Aerie Openings

29

52

(1)

  International license locations are not included in the consolidated store data or the total gross square footage calculation.

(2)

  Aerie side-by-side and OFFLINE side-by-side stores are included in the AE Brand store count as they are considered part of the AE Brand store to which they are attached. OFFLINE side-by-side stores, when attached to an Aerie Brand store, are included in the Aerie Brand store count.

(3)

  Aerie stand-alone stores include 3 OFFLINE openings during the period and 4 OFFLINE openings YTD, with 8 OFFLINE stores in the consolidated totals.

(4)

  Aerie side-by-side stores include 4 OFFLINE openings during the period and YTD, with 5 OFFLINE stores in the consolidated totals.
 
 

 

Olivia Messina

412-432-3300

[email protected]

KEYWORDS: Pennsylvania United States North America

INDUSTRY KEYWORDS: Fashion Online Retail Retail Other Consumer Consumer Other Retail Specialty

MEDIA:

Logo
Logo

Newmont Appoints Two New Board Directors

Newmont Appoints Two New Board Directors

Company Further Strengthens Board’s Industry Experience and Diversity

DENVER–(BUSINESS WIRE)–
Today, Newmont Corporation (NYSE: NEM, TSX:NGT) announced the appointment of Dr. Emma FitzGerald and Mary Laschinger to its Board of Directors effective December 1, 2021.

Emma FitzGerald is the former Chief Executive Officer of Puma Energy International and a leader in delivering energy solutions around the world. Emma has a deep understanding of the energy and water industries and operating successfully in developing markets from leading customer facing downstream businesses during a more than 20 year career with Royal Dutch Shell. She is a member of the Board of UPM Kymmene oyj, the Biofore Company, and serves on the Audit and Remuneration Committees. She is also a member of the Board of Seplat Energy plc, where she serves on the Finance, Energy Transition and Sustainability Committees. She is a portfolio advisor with Oxford Science Enterprises and a mentor on the Creative Destruction Lab Climate stream to help accelerate innovations supporting the energy transition. She also acts as an expert advisor to the World Economic Forum supporting mobilization of financing to drive energy transition in developing markets.

Mary Laschinger is the former Chief Executive Officer of Veritiv, a Fortune 500 business-to-business distribution solutions company. Prior to her time at Veritiv, she was a senior leader at International Paper Company, with valuable global business experience as President of their Europe, Middle East, Africa, and Russia business from 2005 to 2010, as well as holding senior management roles in sales, marketing, manufacturing, and supply chain. She is a member of the Board of Directors of the Federal Reserve Bank of Atlanta, where she chairs the Audit Committee. She is also a member of the Board of Directors for Kellogg Company, where she chairs the Compensation and Talent Management Committee and serves on the Executive and Nominating and Governance Committees.

“We are thrilled to welcome these two experienced and distinguished directors to Newmont,” said Gregory Boyce, Chair of Newmont’s Board of Directors. “Their outstanding senior management experience, comprehensive knowledge of complex global operations and deep understanding of governance and oversight make them excellent additions to our Board.”

“Newmont’s Board of Directors brings a broad range of backgrounds, experiences and talents, along with ethnic and gender diversity, to our governance process,” said Newmont President and CEO Tom Palmer. “Having a diverse Board with deep senior management experience in industry as well as specialized fields is a priority for Newmont. With the addition of Dr. FitzGerald and Ms. Laschinger, Newmont’s Board is further strengthened.”

About Newmont

Newmont is the world’s leading gold company and a producer of copper, silver, zinc and lead. The Company’s world-class portfolio of assets, prospects and talent is anchored in favorable mining jurisdictions in North America, South America, Australia and Africa. Newmont is the only gold producer listed in the S&P 500 Index and is widely recognized for its principled environmental, social and governance practices. The Company is an industry leader in value creation, supported by robust safety standards, superior execution and technical expertise. Newmont was founded in 1921 and has been publicly traded since 1925.

At Newmont, our purpose is to create value and improve lives through sustainable and responsible mining. To learn more about Newmont’s sustainability strategy and initiatives, visit us at www.newmont.com.

Newmont Media Contact

Courtney Boone 303.837.5159 [email protected]

Newmont Investor Contact

Daniel Horton 303.837.5468 [email protected]

KEYWORDS: Colorado United States North America Canada

INDUSTRY KEYWORDS: Energy Natural Resources Other Natural Resources Mining/Minerals

MEDIA:

Logo
Logo

Novocure to Participate in Two Upcoming Investor Conferences

Novocure to Participate in Two Upcoming Investor Conferences

ST. HELIER, Jersey–(BUSINESS WIRE)–
Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.

William Doyle, Novocure’s Executive Chairman, and Ashley Cordova, Novocure’s Chief Financial Officer, will participate in the 33rd Annual 2021 Piper Sandler Healthcare Conference on November 30, 2021. Mr. Doyle and Ms. Cordova will take part in a fireside chat at 1 p.m. EST, as well as one-on-one meetings with investors throughout the event. A live audio webcast of the presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for replay for at least 14 days following the event.

Ms. Cordova will be joined by Pritesh Shah, Novocure’s Chief Commercial Officer, for additional one-on-one meetings with investors as part of the 4th Annual 2021 Evercore ISI HealthCONx Conference on December 2, 2021.

Novocure’s corporate presentation is updated periodically, and the current presentation can be accessed from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations. Novocure has used, and intends to continue to use, its Investor Relations website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and in the U.S. for the treatment of adult patients with malignant pleural mesothelioma. Novocure has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Jersey, and with a growing global footprint, Novocure has regional operating centers in Root, Switzerland, Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical trial progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 25, 2021 with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Investors:

Ingrid Goldberg

[email protected]

610-723-7427

Media:

Leigh Labrie

[email protected]

610-723-7428

KEYWORDS: Jersey Europe

INDUSTRY KEYWORDS: Health Science Research Clinical Trials Oncology

MEDIA:

Logo
Logo

Abercrombie & Fitch Co. Reports Third Quarter Results

Achieves best third quarter operating income and operating margin since 2012

Announces Board of Director’s approval of $500 million share repurchase program

NEW ALBANY, Ohio, Nov. 23, 2021 (GLOBE NEWSWIRE) — Abercrombie & Fitch Co. (NYSE: ANF) today announced results for the third quarter ended October 30, 2021. These compare to results for the third quarter ended October 31, 2020. Descriptions of the use of non-GAAP financial measures and reconciliations of GAAP and non-GAAP financial measures accompany this release.

Fran Horowitz, Chief Executive Officer, said, “We were very pleased with our third quarter results. Total net sales grew 10% year-over-year, or 5% from 2019 levels. Our largest market, the U.S., experienced ongoing strength, growing 17% on a one-year and 12% on a two-year basis. Digital net sales rose 8% from last year, representing 46% of total third quarter sales. Gross profit rate declined 30 basis points on a one-year and increased 360 basis points on a two-year basis, benefiting from AUR improvements, offset by elevated supply chain costs. Combined with ongoing tight expense controls, we achieved an 8% operating margin, representing our best third quarter operating margin and income since 2012.”

“The start of the holiday season has been promising. Customers have come out early to shop and have been responding well to assortments. We continue to actively manage through ongoing supply chain constraints, including production and delivery delays and elevated costs, and are confident that we have the product, marketing voice and omnichannel experience to surprise and delight new and existing customers throughout the fourth quarter.”

Details related to net income per diluted share for the third quarter are as follows:

    2021   2020
GAAP   $ 0.77     $ 0.66  
Excluded items, net of tax effect (1)   (0.09 )   (0.09 )
Adjusted non-GAAP   $ 0.86     $ 0.76  
Impact from changes in foreign currency exchange rates (2)       (0.05 )
Adjusted non-GAAP constant currency   $ 0.86     $ 0.71  

(1)   Excluded items consist of pre-tax store asset impairment charges and the tax effect of pre-tax excluded items.

(2)   The estimated impact from foreign currency is calculated by applying current period exchange rates to prior year results using a 26% tax rate.

A summary of results for the third quarter ended October 30, 2021 as compared to the third quarter ended October 31, 2020:

  • Net sales of $905 million, up 10% as compared to last year and up 5% as compared to pre-COVID 2019 third quarter net sales.
  • Digital net sales of $413 million increased 8% as compared to last year and increased 55% as compared to pre-COVID 2019 third quarter digital net sales.
  • Gross profit rate of 63.7%, down approximately 30 basis points as compared to last year and up approximately 360 basis points as compared to 2019. The year-over-year decline is driven by approximately 300 basis points of higher average unit cost from freight inflation and efforts to offset supply chain issues, almost fully offset by higher average unit retail on lower promotions.
  • Operating expense, excluding other operating income, net, was up 8% compared to last year and remained flat as compared to 2019. The year-over-year increase reflects an increase in marketing expenses and payroll and a decrease in store occupancy. Operating expense as a percentage of sales decreased to 55.8% from 56.8% last year and from 58.4% as compared to 2019.
  • Operating income of $73 million and $79 million on a reported and adjusted non-GAAP basis, respectively, as compared to operating income of $59 million and $65 million last year, on a reported and adjusted non-GAAP basis, respectively.
  • Net income per diluted share of $0.77 and $0.86 on a reported and adjusted non-GAAP basis, respectively, as compared to net income per diluted share last year of $0.66 and $0.76 on a reported and adjusted non-GAAP basis, respectively.
Net Sales

Net sales by brand and region for the third quarter are as follows:

(in thousands) 2021   2020   2019   1 YR % Change   2 YR % Change
Net sales by brand:                  
Hollister (1) $ 522,311     $ 476,665     $ 514,772     10%   1%
Abercrombie (2) 382,849     342,988     348,700     12%   10%
Total company $ 905,160     $ 819,653     $ 863,472     10
%
  5
%
                   
Net sales by region:

(3)
2021   2020   2019   1 YR % Change   2 YR % Change
United States $ 654,858     $ 557,814     $ 583,593     17%   12%
EMEA 179,156     190,214     191,977     (6)%   (7)%
APAC 38,215     43,618     55,910     (12)%   (32)%
Other (4) 32,931     28,007     31,992     18%   3%
International $ 250,302     $ 261,839     $ 279,879     (4)%   (11)%
Total company $ 905,160     $ 819,653     $ 863,472     10
%
  5
%

(1)   Hollister includes the Hollister, Gilly Hicks and Social Tourist brands.

(2)   Abercrombie includes the Abercrombie & Fitch and abercrombie kids brands.

(3)   Net sales by geographic area are presented by attributing revenues to an individual country on the basis of the country in which the merchandise was sold for in-store purchases and on the basis of the shipping location provided by customers for digital orders.

(4)   Other includes all sales that do not fall within the United States, EMEA, or APAC regions.

Financial Position and Liquidity

As of October 30, 2021 the company had:

  • Cash and equivalents of $0.9 billion. This compares to cash and equivalents of $1.1 billion and $0.8 billion as of January 30, 2021 and October 31, 2020, respectively.
  • Inventories of $544 million, steady compared to October 31, 2020.
  • Long-term gross borrowings under the company’s senior secured notes of $308 million (the “Senior Secured Notes”) which mature in July 2025 and bear interest at a rate of 8.75% per annum.
  • Borrowing available under the senior-secured asset-based revolving credit facility (the “ABL Facility”) of $271 million.
  • Liquidity, comprised of cash and equivalents and borrowing available under the ABL Facility, of approximately $1.1 billion. This compares to liquidity of $1.3 billion and $1.2 billion as of January 30, 2021 and October 31, 2020, respectively.
Cash Flow and Capital Allocation

Details related to the company’s cash flows for the year-to-date period ended October 30, 2021 are as follows:

  • Net cash provided by operating activities of $131 million.
  • Net cash used for investing activities of $62 million.
  • Net cash used for financing activities of $304 million.

The company repurchased approximately 2.7 million shares during the third quarter and has returned $235 million to shareholders during the year-to-date period ended October 30, 2021 through share repurchases. The company’s Board of Directors approved a new share repurchase program of up to $500 million of outstanding common stock, replacing the February 2021 share repurchase program of 10 million shares, which had approximately 3.9 million shares remaining. The timing and actual number of common shares to be repurchased will depend upon market conditions, eligibility to trade, and other factors.

During the second quarter of fiscal 2021, the company spent $47 million to purchase $42.3 million at par value of its senior secured notes. During the first quarter of fiscal 2021, the company paid $64 million to settle all remaining obligations related to the SoHo Hollister flagship store in New York City, which reduced the company’s operating lease liabilities by $65 million and eliminated future interest expense related to this obligation.

Depreciation and amortization was $108 million for the year-to-date period ended October 30, 2021.

Conference Call

Today at 8:30 AM, ET, the company will conduct a conference call and provide additional details around its quarterly results and its outlook for the fourth quarter. To listen to the conference call, dial (800) 458-4121 or go to corporate.abercrombie.com. The international call-in number is (323) 794-2093. This call will be recorded and made available by dialing the replay number (888) 203-1112 or the international number (719) 457-0820 followed by the conference ID number 1289887 or through corporate.abercrombie.com. A presentation of third quarter results will be available in the “Investors” section at corporate.abercrombie.com at approximately 7:30 AM, ET, today.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

A&F cautions that any forward-looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) contained in this Press Release or made by management or spokespeople of A&F involve risks and uncertainties and are subject to change based on various important factors, many of which may be beyond the company’s control. Words such as “estimate,” “project,” “plan,” “believe,” “expect,” “anticipate,” “intend,” “should,” “are confident,” and similar expressions may identify forward-looking statements. Except as may be required by applicable law, we undertake no obligation to publicly update or revise any forward-looking statements. The following factors, in addition to those disclosed in “ITEM 1A. RISK FACTORS” of A&F’s Annual Report on Form 10-K for the fiscal year ended January 30, 2021, in some cases have affected, and in the future could affect, A&F’s financial performance and could cause actual results for fiscal 2021 and beyond to differ materially from those expressed or implied in any of the forward-looking statements included in this Press Release or otherwise made by management: COVID‐19 has and may continue to materially adversely impact and cause disruption to our business; changes in global economic and financial conditions, and the resulting impact on consumer confidence and consumer spending, as well as other changes in consumer discretionary spending habits could have a material adverse impact on our business; failure to engage our customers, anticipate customer demand and changing fashion trends, and manage our inventory commensurately could have a material adverse impact on our business; our failure to operate effectively in a highly competitive and constantly evolving industry could have a material adverse impact on our business; fluctuations in foreign currency exchange rates could have a material adverse impact on our business; our ability to attract customers to our stores depends, in part, on the success of the shopping malls or area attractions that our stores are located in or around; the impact of war, acts of terrorism, mass casualty events, social unrest, civil disturbance or disobedience could have a material adverse impact on our business; the impact of extreme weather, infectious disease outbreaks, including COVID-19, and other unexpected events could result in an interruption to our business, as well as to the operations of our third-party partners, and have a material adverse impact on our business; failure to successfully develop an omnichannel shopping experience, a significant component of our growth strategy, or failure to successfully invest in customer, digital and omnichannel initiatives could have a material adverse impact on our business; our failure to optimize our global store network could have a material adverse impact on our business; our failure to execute our international growth strategy successfully and inability to conduct business in international markets as a result of legal, tax, regulatory, political and economic risks could have a material adverse impact on our business; our failure to appropriately address emerging environmental, social and governance matters could have a material adverse impact on our reputation and, as a result, our business; failure to protect our reputation could have a material adverse impact on our business; if our information technology systems are disrupted or cease to operate effectively, it could have a material adverse impact on our business; we may be exposed to risks and costs associated with cyber-attacks, data protection, credit card fraud and identity theft that could have a material adverse impact on our business; our reliance on our distribution centers makes us susceptible to disruptions or adverse conditions affecting our supply chain; changes in the cost, availability and quality of raw materials, labor, transportation, and trade relations could have a material adverse impact on our business; we depend upon independent third parties for the manufacture and delivery of all our merchandise, and a disruption of the manufacture or delivery of our merchandise could have a material adverse impact on our business; we rely on the experience and skills of our executive officers and associates, and the failure to attract or retain this talent, effectively manage succession, and establish a diverse workforce could have a material adverse impact on our business; in the past, we have identified a material weakness in our internal control over financial reporting and may identify additional material weaknesses in the future. If we fail to establish and maintain effective internal control over financial reporting, our ability to accurately and timely report our financial results could be adversely affected; fluctuations in our tax obligations and effective tax rate may result in volatility in our results of operations could have a material adverse impact on our business; our litigation exposure, or any securities litigation and shareholder activism, could have a material adverse impact on our business; failure to adequately protect our trademarks could have a negative impact on our brand image and limit our ability to penetrate new markets which could have a material adverse impact on our business; changes in the regulatory or compliance landscape could have a material adverse impact on our business; and the agreements related to our senior secured asset-based revolving credit facility and our senior secured notes include restrictive covenants that limit our flexibility in operating our business and our inability to obtain credit on reasonable terms in the future could have an adverse impact on our business.

About Abercrombie & Fitch Co.

Abercrombie & Fitch Co. (NYSE: ANF) is a leading, global, omnichannel specialty retailer of apparel and accessories for men, women and kids through five renowned brands. The iconic Abercrombie & Fitch brand was born in 1892 and aims to make every day feel as exceptional as the start of a long weekend. abercrombie kids sees the world through kids’ eyes, where play is life and every day is an opportunity to be anything and better anything. The Hollister brand believes in liberating the spirit of an endless summer inside everyone and making teens feel celebrated and comfortable in their own skin. Gilly Hicks, offering intimates, loungewear and sleepwear, is designed to give all Gen Z customers their daily dose of happy. Social Tourist, the creative vision of Hollister and social media personalities, Dixie and Charli D’Amelio, offers trend forward apparel that allows teens to experiment with their style, while exploring the duality of who they are both on social media and in real life.

The brands share a commitment to offering products of enduring quality and exceptional comfort that allow consumers around the world to express their own individuality and style. Abercrombie & Fitch Co. operates approximately 730 stores under these brands across North America, Europe, Asia and the Middle East, as well as the e-commerce sites www.abercrombie.com, www.abercrombiekids.com, www.hollisterco.com, www.gillyhicks.com and www.socialtourist.com.

Investor Contact:   Media Contact:
     
Pamela Quintiliano   Mackenzie Gusweiler
Abercrombie & Fitch Co.   Abercrombie & Fitch Co.
(614) 283-6751   (614) 283-6192
[email protected]   [email protected]

Abercrombie & Fitch Co.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
               
  Thirteen Weeks Ended   Thirteen Weeks Ended
  October 30, 2021   % of
Net Sales
  October 31, 2020   % of
Net Sales
Net sales $ 905,160     100.0 %   $ 819,653     100.0 %
Cost of sales, exclusive of depreciation and amortization 328,916     36.3 %   295,220     36.0 %
Gross profit 576,244     63.7 %   524,433     64.0 %
Stores and distribution expense 351,804     38.9 %   346,263     42.2 %
Marketing, general and administrative expense 146,269     16.2 %   121,000     14.8 %
Flagship store exit benefits (costs) 11     0.0 %   (8,063 )   (1.0 )%
Asset impairment, exclusive of flagship store exit charges 6,749     0.7 %   6,329     0.8 %
Other operating (income) expense, net (1,320 )   (0.1 )%   288     0.0 %
Operating income 72,731     8.0 %   58,616     7.2 %
Interest expense, net 7,270     0.8 %   8,808     1.1 %
Income before income taxes 65,461     7.2 %   49,808     6.1 %
Income tax expense 16,383     1.8 %   5,779     0.7 %
Net income 49,078     5.4 %   44,029     5.4 %
Less: Net income attributable to noncontrolling interests 1,845     0.2 %   1,758     0.2 %
Net income attributable to Abercrombie & Fitch Co. $ 47,233     5.2 %   $ 42,271     5.2 %
               
Net income per share attributable to Abercrombie & Fitch Co.:              
Basic $ 0.80         $ 0.68      
Diluted $ 0.77         $ 0.66      
               
Weighted-average shares outstanding:              
Basic 58,796         62,558      
Diluted 61,465         63,877      
               

Abercrombie & Fitch Co.
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(Unaudited)
               
  Thirty-nine Weeks Ended   Thirty-nine Weeks Ended
  October 30, 2021   % of
Net Sales
  October 31, 2020   % of
Net Sales
Net sales $ 2,551,415     100.0 %   $ 2,003,340     100.0 %
Cost of sales, exclusive of depreciation and amortization 916,552     35.9 %   791,154     39.5 %
Gross profit 1,634,863     64.1 %   1,212,186     60.5 %
Stores and distribution expense 994,347     39.0 %   978,757     48.9 %
Marketing, general and administrative expense 391,129     15.3 %   326,509     16.3 %
Flagship store exit benefits (1,177 )   0.0 %   (12,490 )   (0.6 )%
Asset impairment, exclusive of flagship store exit charges 10,199     0.4 %   57,340     2.9 %
Other operating income, net (4,586 )   (0.2 )%   (1,562 )   (0.1 )%
Operating income (loss) 244,951     9.6 %   (136,368 )   (6.8 )%
Interest expense, net 27,151     1.1 %   19,277     1.0 %
Income (loss) before income taxes 217,800     8.5 %   (155,645 )   (7.8 )%
Income tax expense 15,560     0.6 %   38,565     1.9 %
Net income (loss) 202,240     7.9 %   (194,210 )   (9.7 )%
Less: Net income attributable to noncontrolling interests 4,739     0.2 %   2,203     0.1 %
Net income (loss) attributable to Abercrombie & Fitch Co. $ 197,501     7.7 %   $ (196,413 )   (9.8 )%
               
Net income (loss) per share attributable to Abercrombie & Fitch Co.:              
Basic $ 3.24         $ (3.14 )    
Diluted $ 3.10         $ (3.14 )    
               
Weighted-average shares outstanding:              
Basic 60,879         62,541      
Diluted 63,770         62,541      
               

Reporting and Use of GAAP and Non-GAAP Measures

The company believes that each of the non-GAAP financial measures presented are useful to investors as they provide a measure of the company’s operating performance excluding the effect of certain items which the company believes do not reflect its future operating outlook, such as asset impairment charges primarily attributable to the COVID-19 pandemic or related to the company’s flagship stores, therefore supplementing investors’ understanding of comparability of operations across periods. Management used these non-GAAP financial measures during the periods presented to assess the company’s performance and to develop expectations for future operating performance. Non-GAAP financial measures should be used supplemental to, and not as an alternative to, the company’s GAAP financial results, and may not be calculated in the same manner as similar measures presented by other companies.

In addition, at times the company provides comparable sales, defined as the percentage year-over-year change in the aggregate of: (1) sales for stores that have been open as the same brand at least one year and whose square footage has not been expanded or reduced by more than 20% within the past year, with prior year’s net sales converted at the current year’s foreign currency exchange rate to remove the impact of foreign currency rate fluctuation, and (2) digital net sales with prior year’s net sales converted at the current year’s foreign currency exchange rate to remove the impact of foreign currency rate fluctuation. In light of store closures related to COVID-19, the Company has not disclosed comparable sales for Fiscal 2021.

The company also provides certain financial information on a constant currency basis to enhance investors’ understanding of underlying business trends and operating performance, by removing the impact of foreign currency exchange rate fluctuations. The effect from foreign currency, calculated on a constant currency basis, is determined by applying current year average exchange rates to prior year results and is net of the year-over-year impact from hedging. The per diluted share effect from foreign currency is calculated using a 26% tax rate.

Abercrombie & Fitch Co.
Schedule of Non-GAAP Financial Measures
Thirteen Weeks Ended October 30, 2021
(in thousands, except per share data)
(Unaudited)
           
  GAAP (1)   Excluded items   Adjusted
non-GAAP
Asset impairment, exclusive of flagship store exit charges (2) $ 6,749     $ 6,749     $  
Operating income 72,731     (6,749 )   79,480  
Income before income taxes 65,461     (6,749 )   72,210  
Income tax expense (3) 16,383     (1,375 )   17,758  
Net income attributable to Abercrombie & Fitch Co. $ 47,233     $ (5,374 )   $ 52,607  
           
Net income per diluted share attributable to Abercrombie & Fitch Co. $ 0.77     $ (0.09 )   $ 0.86  
Diluted weighted-average shares outstanding: 61,465         61,465  

(
1)   “GAAP” refers to accounting principles generally accepted in the United States of America.

(2)   Excluded items consist of pre-tax store asset impairment charges of $6.7 million.

(3)   The tax effect of excluded items is the difference between the tax provision calculated on a GAAP basis and an adjusted non-GAAP basis.

Abercrombie & Fitch Co.
Schedule of Non-GAAP Financial Measures
Thirteen Weeks Ended October 31, 2020
(in thousands, except per share data)
(Unaudited)
           
  GAAP (1)   Excluded items   Adjusted
non-GAAP
Asset impairment, exclusive of flagship store exit charges (2) $ 6,329     $ 6,329     $  
Operating income 58,616     (6,329 )   64,945  
Income before income taxes 49,808     (6,329 )   56,137  
Income tax expense (3) 5,779     (369 )   6,148  
Net income attributable to Abercrombie & Fitch Co. $ 42,271     $ (5,960 )   $ 48,231  
           
Net income per diluted share attributable to Abercrombie & Fitch Co. $ 0.66     $ (0.09 )   $ 0.76  
Diluted weighted-average shares outstanding: 63,877         63,877  

(1)   “GAAP” refers to accounting principles generally accepted in the United States of America.

(2)   Excluded items consist of pre-tax store asset impairment charges of $6.3 million, which are principally the result of the impact of COVID-19 on store cash flows.

(3)   The tax effect of excluded items is the difference between the tax provision calculated on a GAAP basis and an adjusted non-GAAP basis.

Abercrombie & Fitch Co.
Schedule of Non-GAAP Financial Measures
Thirty-nine Weeks Ended October 30, 2021
(in thousands, except per share data)
(Unaudited)
           
  GAAP (1)   Excluded items   Adjusted
non-GAAP
Asset impairment, exclusive of flagship store exit charges (2) $ 10,199     $ 10,199     $  
Operating income 244,951     (10,199 )   255,150  
Income before income taxes 217,800     (10,199 )   227,999  
Income tax expense (3) 15,560     (2,048 )   17,608  
Net income attributable to Abercrombie & Fitch Co. $ 197,501     $ (8,151 )   $ 205,652  
           
Net income per diluted share attributable to Abercrombie & Fitch Co. $ 3.10     $ (0.13 )   $ 3.22  
Diluted weighted-average shares outstanding: 63,770         63,770  

(
1)   “GAAP” refers to accounting principles generally accepted in the United States of America.

(2)   Excluded items consist of pre-tax store asset impairment charges of $10.2 million.

(3)   The tax effect of excluded items is the difference between the tax provision calculated on a GAAP basis and an adjusted non-GAAP basis.

Abercrombie & Fitch Co.
Schedule of Non-GAAP Financial Measures
Thirty-nine Weeks Ended October 31, 2020
(in thousands, except per share data)
(Unaudited)
           
  GAAP (1)   Excluded items   Adjusted
non-GAAP
Asset impairment, exclusive of flagship store exit charges (2) $ 57,340     $ 57,340     $  
Operating loss (136,368 )   (57,340 )   (79,028 )
Loss before income taxes (155,645 )   (57,340 )   (98,305 )
Income tax expense (3) 38,565     (3,635 )   42,200  
Net loss attributable to Abercrombie & Fitch Co. $ (196,413 )   $ (53,705 )   $ (142,708 )
           
Net loss per diluted share attributable to Abercrombie & Fitch Co. $ (3.14 )   $ (0.86 )   $ (2.28 )
Diluted weighted-average shares outstanding: 62,541         62,541  

(1)   “GAAP” refers to accounting principles generally accepted in the United States of America.

(2)   Excluded items consist of pre-tax store asset impairment charges of $57.3 million, which are principally the result of the impact of COVID-19 on store cash flows.

(3)   The tax effect of excluded items is the difference between the tax provision calculated on a GAAP basis and an adjusted non-GAAP basis.

Abercrombie & Fitch Co.
Reconciliation of Constant Currency Financial Measures
Thirteen Weeks Ended October 30, 2021
(in thousands, except percentage and basis point changes and per share data)
(Unaudited)
           
  2021   2020   % Change
Net sales          
GAAP (1) $ 905,160     $ 819,653     10%
Impact from changes in foreign currency exchange rates (2)     3,540     —%
Net sales on a constant currency basis $ 905,160     $ 823,193     10%
           
Gross profit 2021   2020   BPS Change (3)
GAAP (1) $ 576,244     $ 524,433     (30)
Impact from changes in foreign currency exchange rates (2)     (1,702 )   50
Gross profit on a constant currency basis $ 576,244     $ 522,731     20
           
Operating income 2021   2020   BPS Change (3)
GAAP (1) $ 72,731     $ 58,616     80
Excluded items (4) (6,749 )   (6,329 )   10
Adjusted non-GAAP $ 79,480     $ 64,945     90
Impact from changes in foreign currency exchange rates (2)     (4,067 )   50
Adjusted non-GAAP constant currency basis $ 79,480     $ 60,878     140
           
Net income per diluted share attributable to Abercrombie & Fitch Co. 2021   2020   $ Change
GAAP (1) $ 0.77     $ 0.66     $0.11
Excluded items, net of tax (4) (0.09 )   (0.09 )   0.00
Adjusted non-GAAP $ 0.86     $ 0.76     $0.10
Impact from changes in foreign currency exchange rates (2)     (0.05 )   0.05
Adjusted non-GAAP constant currency basis $ 0.86     $ 0.71     $0.15

(1)   “GAAP” refers to accounting principles generally accepted in the United States of America.

(2)   The estimated impact from foreign currency is determined by applying current period exchange rates to prior year results and is net of the year-over-year impact from hedging. The per diluted share estimated impact from foreign currency is calculated using a 26% tax rate.

(3)   The estimated basis point change has been rounded based on the percentage change.

(4)   Excluded items consist of pre-tax store asset impairment charges of $6.7 million and $6.3 million for the current year and prior year, respectively.

Abercrombie & Fitch Co.
Condensed Consolidated Balance Sheets
(in thousands)
(Unaudited)
           
  October 30, 2021   January 30, 2021   October 31, 2020
Assets          
Current assets:          
Cash and equivalents $ 865,622     $ 1,104,862     $ 812,881  
Receivables 83,447     83,857     89,074  
Inventories 543,713     404,053     545,548  
Other current assets 111,423     68,857     73,776  
Total current assets 1,604,205     1,661,629     1,521,279  
Property and equipment, net 516,176     550,587     593,932  
Operating lease right-of-use assets 762,641     893,989     955,781  
Other assets 229,512     208,697     205,970  
Total assets $ 3,112,534     $ 3,314,902     $ 3,276,962  
           
Liabilities and stockholders’ equity          
Current liabilities:          
Accounts payable $ 424,560     $ 289,396     $ 334,775  
Accrued expenses 355,149     396,365     356,370  
Short-term portion of operating lease liabilities 209,812     248,846     255,775  
Income taxes payable 39,900     24,792     6,663  
Total current liabilities 1,029,421     959,399     953,583  
Long-term liabilities:          
Long-term portion of operating lease liabilities $ 764,346     $ 957,588     $ 1,010,051  
Long-term borrowings, net 303,247     343,910     343,559  
Other liabilities 97,191     104,693     110,965  
Total long-term liabilities 1,164,784     1,406,191     1,464,575  
Total Abercrombie & Fitch Co. stockholders’ equity 908,934     936,628     849,379  
Noncontrolling interests 9,395     12,684     9,425  
Total stockholders’ equity 918,329     949,312     858,804  
Total liabilities and stockholders’ equity $ 3,112,534     $ 3,314,902     $ 3,276,962  

Abercrombie & Fitch Co.
Condensed Consolidated Statements of Cash Flows
(in thousands, except per share data)
(Unaudited)
       
       
  Thirty-nine Weeks Ended
  October 30, 2021   October 31, 2020
Operating activities      
Net cash provided by operating activities $ 131,287     $ 108,894  
       
Investing activities      
Purchases of property and equipment $ (62,223 )   $ (91,748 )
Withdrawal of funds from Rabbi Trust assets (1)     50,000  
Net cash used for investing activities $ (62,223 )   $ (41,748 )
       
Financing activities      
Proceeds from issuance of senior secured notes     350,000  
Proceeds from borrowings under the asset-based senior secured credit facility     210,000  
Repayment of term loan facility borrowings     (233,250 )
Repayment of borrowings under the asset-based senior secured credit facility     (210,000 )
Purchase of senior secured notes (46,969 )    
Payment of debt issuance or modification costs and fees (2,016 )   (7,151 )
Purchases of common stock (235,249 )   (15,172 )
Dividends paid     (12,556 )
Other financing activities (20,124 )   (11,742 )
Net cash (used for) provided by financing activities $ (304,358 )   $ 70,129  
       
Effect of foreign currency exchange rates on cash $ (8,560 )   $ 2,269  
Net (decrease) increase in cash and equivalents, and restricted cash and equivalents $ (243,854 )   $ 139,544  
Cash and equivalents, and restricted cash and equivalents, beginning of period $ 1,124,157     $ 692,264  
Cash and equivalents, and restricted cash and equivalents, end of period $ 880,303     $ 831,808  

(1)   As disclosed in the Form 10-K for the year ended January 30, 2021, during the fourth quarter ended January 30, 2021, an error relating to the cash flow presentation of the $50 million withdrawal of the excess funds from the company’s Rabbi Trust assets was identified. The cash flows presented for the year-to-date periods ended May 2, 2020, August 1, 2020, and October 31, 2020 incorrectly classified such withdrawal as a cash inflow from operating activities, rather than a cash inflow from investing activities. This cash flow statement reflects the correct classification.

Abercrombie & Fitch Co.

Store Count

  Thirteen Weeks Ended October 30, 2021
  Hollister

(1)
  Abercrombie

(2)
  Total Company

(3)
  United States   International   United States   International   United States   International   Total
July 31, 2021 355   150   179   49   534   199   733
New 1   1   2   1   3   2   5
Permanently closed (1)       (2)   (1)   (2)   (3)
October 30, 2021 355   151   181   48   536   199   735
                           
  Thirty-Nine Weeks Ended October 30, 2021    
  Hollister

(1)
  Abercrombie
(2)
  Total Company

(3)
  United States   International   United States   International   United States   International   Total
January 30, 2021 347   150   190   48   537   198   735
New 9   5   6   3   15   8   23
Permanently closed (1)   (4)   (15)   (3)   (16)   (7)   (23)
October 30, 2021 355   151   181   48   536   199   735

(1)   Hollister includes the company’s Hollister and Gilly Hicks brands. Locations with Gilly Hicks carveouts within Hollister stores are represented as a single store count. Excludes 10 international franchise stores as of October 30, 2021, 10 international franchise stores as of July 31, 2021, and 9 international franchise stores as of January 30, 2021. Excludes 14 Company-operated temporary stores as of each of October 30, 2021 and July 31, 2021, and 12 Company-operated temporary stores as of January 30, 2021.

(2)   Abercrombie includes the company’s Abercrombie & Fitch and abercrombie kids brands. Locations with abercrombie kids carveouts within Abercrombie & Fitch stores are represented as a single store count. Excludes 13 international franchise stores as of October 30, 2021, 12 international franchise stores as of and July 31, 2021, and 10 international franchise stores as of January 30, 2021. Excludes four Company-operated temporary stores as of each of October 30, 2021 and July 31, 2021, and two Company-operated temporary stores as of January 30, 2021.

(3)   This store count excludes one international third-party operated multi-brand outlet store as of each of October 30, 2021, July 31, 2021, and January 30, 2021.



Monro, Inc. Declares Quarterly Cash Dividend

ROCHESTER, N.Y., Nov. 23, 2021 (GLOBE NEWSWIRE) — Monro, Inc. (Nasdaq: MNRO), a leading provider of automotive undercar repair and tire services, today announced that its Board of Directors has declared a quarterly cash dividend of $.26 per share on the Company’s outstanding shares of common stock, including the shares of common stock to which the holders of the Company’s Class C Convertible Preferred Stock are entitled. The dividend is payable on December 21, 2021 to shareholders at the close of business on December 7, 2021.


About Monro, Inc.

Monro, Inc. (NASDAQ: MNRO) is one of the nation’s leading automotive service and tire providers, delivering best-in-class auto care to communities across the country, from oil changes, tires and parts installation, to the most complex vehicle repairs. With a growing market share and a focus on sustainable growth, the Company generated $1.1 billion in sales in fiscal 2021 and continues to expand its national presence through strategic acquisitions and the opening of newly constructed stores. Across nearly 1,300 stores and 9,000 service bays nationwide, Monro brings customers the professionalism and high-quality service they expect from a national retailer, with the convenience and trust of a neighborhood garage. Monro’s highly-trained teammates and certified technicians bring together hands-on experience and state-of-the-art technology to diagnose and address automotive needs every day to get customers back on the road safely. For more information, please visit www.monro.com.



CONTACT: 
Kim Rudd
Executive Assistant
(585) 784-3324

Investors and Media: 
Doug Cooper
FTI Consulting
(212) 850-5600